Navigation Links
Sosei Announces Outcome of Strategy Review
Date:5/13/2008

TOKYO, May 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the outcome of its strategy review.

In view of the current market conditions, the difficulty in raising finance at the current low share price, and the problems associated with the AD923 device which has necessitated a halt to the Phase III trials Sosei has taken decisive action to cut costs, streamline its operation and to secure the future of the business until it becomes a significant income generating business from NVA237/QVA149 in a few years time.

- Sosei is closing its Chesterford operation and Sosei R&D's

continuing business will relocate to London in due course. This will

reduce UK headcount by c 40 staff and provide a full years cost saving of

around $4M.

- Sosei will no longer operate a drug discovery unit.

- Sosei R&D will maintain the rights to NVA237/QVA149 but seek

to out-license or sell all other assets generated in the UK including

AD923 and its discovery assets whilst seeking to retain some rights for

the Asian market.

- Tokyo will continue to develop Norlevo and explore other

in-licensing opportunities.

This restructuring and portfolio review will provide Sosei with at least two years cash based on the post-restructuring cash burn including a budget allocation to explore some late stage product opportunities for future expansion but without the inclusion of any income from licensing or sales deals for its compounds.

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical mark
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
2. BD Announces Acquisition of Cytopeia
3. Chindex International Announces Shelf Registration, Related Strategy and Guidance
4. Amicus Therapeutics Announces First Quarter 2008 Financial Results
5. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
6. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
7. China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
11. Aton Pharma Announces Distribution Partnership in Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... British Columbia , Feb. 27, 2015   ... leader in synthetic biology, today announced it has entered ... (OSF), the pioneering agricultural company behind the Arctic ... Through the acquisition, Intrexon expands its food programs to ... convenient for consumers while providing economic benefit throughout the ...
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine”) (TSX: ... today announced that the U.S. Food and Drug ... designation and Phase I clinical trials of the ... mutual co-development agreement signed with Gilead Life Sciences. ... for the DPX-Survivac. , “We have been in ...
(Date:2/27/2015)... FamilyFarms Group is pleased to announce its valued ... received the 2015 Tomorrow’s Top Producer Horizon Award. The ... 35, who has demonstrated excellence in the business of ... Tomorrow's Top Producer Horizon Award. Every year I look ... and learning from their experiences. It is truly humbling ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... Bulletin Board: GNTA) today announced financial results,for the quarter ... the second quarter, including the following:, -- NDA ... -- AGENDA Phase 3 trial of Genasense in melanoma ... a leading, clinical-stage oral taxane,lifted by FDA, ...
... TORONTO, Aug. 7 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: ... for the early,detection of diseases and personalized health ... second quarter and year to date,ended June 30, ... product, ColonSentry(TM), a blood,test to assess a patient,s ...
... commercially achieved F.O.G. (fats, oils, grease) wastewater treatment system, and ... , ... San Marcos, CA (PRWEB) ... Inc __title__ Green Technology for the Hospitality Industry] announces the ...
Cached Biology Technology:Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 2Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 3Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 4Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 5Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 6Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 7Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 8Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 9Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 10GeneNews Announces Second Quarter Results 2GeneNews Announces Second Quarter Results 3GeneNews Announces Second Quarter Results 4GeneNews Announces Second Quarter Results 5GeneNews Announces Second Quarter Results 6GeneNews Announces Second Quarter Results 7GeneNews Announces Second Quarter Results 8Grease Reduction System a Break Through in Truly "Green" Technology for Luxury Resort 2Grease Reduction System a Break Through in Truly "Green" Technology for Luxury Resort 3
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... 3, 2008 -- Rice University nanophotonics pioneer Naomi Halas ... Research Excellence Award from the University of Pennsylvania,s Nano/Bio ... her numerous contributions in the innovative synthesis of nanostructures. ... address at NBIC,s NanoDay@Penn ceremonies Oct. 29 in Philadelphia. ...
... Erec Stebbins, associate professor at The Rockefeller University, has ... Institutes of Health for a project aimed at exploiting ... into specific cells for therapeutic purposes. The award, which ... by the NIH September 3. The EUREKA program ...
... the American Museum of Natural History have received a ... explore plant evolution and to create a public database ... of proteins found in two plant genomes. The three-year ... investigate ground-breaking methods for exploring the evolution, structure, and ...
Cached Biology News:C. Erec Stebbins awarded prestigious EUREKA grant 2NYU, American Museum of Natural History receive $1.6 million NSF grant 2